Company Description
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases.
The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types.
Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 11, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | David Campbell |
Contact Details
Address: 10955 Vista Sorrento Parkway, Suite 200 San Diego, California 92130 United States | |
| Phone | 858 751 4493 |
| Website | januxrx.com |
Stock Details
| Ticker Symbol | JANX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1817713 |
| CUSIP Number | 47103J105 |
| ISIN Number | US47103J1051 |
| Employer ID | 82-2289112 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Alan Campbell Ph.D. | President, Chief Executive Officer and Director |
| Dr. Thomas Diraimondo Ph.D. | Chief Scientific Officer |
| Matt Whitmire | Vice President of Finance |
| Maria Dobek | Vice President of Accounting |
| Charles M. Winter | Chief Technical Officer |
| James Pennington | General Counsel and Corporate Secretary |
| Janeen Doyle | Chief Corporate and Business Development Officer |
| Dr. William Y. Go M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Feb 6, 2026 | SCHEDULE 13G | Filing |
| Jan 26, 2026 | 144 | Filing |
| Jan 23, 2026 | 144 | Filing |
| Jan 22, 2026 | 8-K | Current Report |
| Jan 8, 2026 | SCHEDULE 13G/A | Filing |